US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Parabilis Medicines, Inc. (PBLS): Biotech Targeting Desmoid Tumor Sets Terms for IPO

Parabilis Medicines, Inc. (PBLS): Regeneron Validation Powers Parabilis Toward Public Markets

Parabilis Medicines, Inc. (PBLS): IPO Prices Above Range, Opens with Massive First-Day Pop

IPOs and Secondary Offerings

Equity Capital Markets

Parabilis Medicines / Equity Capital Markets

<ul>
<li>Parabilis Medicines filed its IPO on May 19, updated offering terms on June 4, and is set to debut on June 10 as it transitions into a public biotech company. </li>
<li>The company plans to offer 25 million shares in a $17–$19 price range, implying an estimated $1.9 billion to $2.1 billion market capitalization at pricing.</li>
<li>The offering provides exposure to its Helicon™ platform targeting historically undruggable proteins, highlighted by early clinical validation in oncology indications.</li>
</ul>


Parabilis Medicines filed its IPO on May 19, updated offering terms on June 4, and is set to debut on June 10 as it transitions into a public biotech company. 
The company plans to offer 25 million shares in a $17–$19 price range, implying an estimated $1.9 billion to $2.1 billion market capitalization at pricing.
The offering provides exposure to its Helicon™ platform targeting historically undruggable proteins, highlighted by early clinical validation in oncology indications.


Parabilis Medicines, Inc. (PBLS): Peeking at the IPO Prospectus of a Peptide Therapeutic Company